Mafenide Hydrochloride | CAS# 138-37-4 | Antibiotic

MedKoo Cat#: 564091 | Name: Mafenide Hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mafenide Hydrochloride is an antibiotic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa.

Chemical Structure

Mafenide Hydrochloride

CAS#138-37-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 564091

Name: Mafenide Hydrochloride

CAS#: 138-37-4 (HCl)

Chemical Formula: C7H11ClN2O2S

Exact Mass: 222.0230

Molecular Weight: 222.69

Elemental Analysis: C, 37.76; H, 4.98; Cl, 15.92; N, 12.58; O, 14.37; S, 14.40

Price and Availability

Size	Price	Availability	Quantity
5g	USD 250.00	2 weeks
25g	USD 450.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

138-39-6 (free base) 12001-72-8 (propionate) 138-37-4 (HCl) 13009-99-9 (acetate)

Synonym

Marfanil; 4-Aminomethylbenzenesulfonamide hydrochloride; Mafenide Hydrochloride

IUPAC/Chemical Name

4-(Aminomethyl)benzenesulfonamide hydrochloride

InChi Key

SIACJRVYIPXFKS-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H10N2O2S.ClH/c8-5-6-1-3-7(4-2-6)12(9,10)11;/h1-4H,5,8H2,(H2,9,10,11);1H

SMILES Code

O=S(C1=CC=C(CN)C=C1)(N)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Mafenide hydrochloride is an effective sulfonamide-type antimicrobial agent used for burn wounds.

In vitro activity:

MAF (mafenide) could inhibit pyroptosis in iBMDM and microglia BV2, and decrease the release of inflammatory factors. MAF could inhibit GSDMD cleavage by directly binding to the GSDMD-Asp275 site, while the expression of p30-GSDMD was simultaneously down-regulated and the release of inflammatory factors was decreased. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/

In vivo activity:

MAF (mafenide) could reduce the levels of inflammatory factors in cerebrospinal fluid and peripheral blood of APP/PS1 mice, and suppress the activation of microglia. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/

	Solvent	mg/mL	mM
Solubility
	Ethanol	8.0	35.92
	Water	44.0	197.59

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 222.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407.

In vitro protocol:

In vivo protocol:

1: Mendelson JA. Topical mafenide hydrochloride aqueous spray in initial management of massive contaminated wounds with devitalized tissue. Prehosp Disaster Med. 2001 Jul-Sep;16(3):172-4. Review. PubMed PMID: 11875802. 2: Mendelson JA. The management of burns under conditions of limited resources using topical aqueous sulfamylon (mafenide) hydrochloride spray. J Burn Care Rehabil. 1997 May-Jun;18(3):238-44. PubMed PMID: 9169948. 3: Holder IA. Wet disc testing of mafenide hydrochloride, chlorhexidine gluconate, and triple antibiotic solution against bacteria isolated from burn wounds. J Burn Care Rehabil. 1990 Jul-Aug;11(4):301-4. PubMed PMID: 2401684. 4: Mendelson JA, Pratt HJ, Amato JJ, Lieberman MK, Hamm TE, Gruber RP, Brinkley FB, Heitkamp DH, Healy MJ. Mafenide hydrochloride and mafenide acetate in spray and ointment forms as topical therapy of C. perfringens contaminated massive wounds: experimental study. J Trauma. 1970 Dec;10(12):1132-44. PubMed PMID: 4320694. 5: Skulan TW, Hoppe JO. Preliminary observations on the toxicity of the hydrochloride and acetate salts of mafenide (sulfamylon r). Life Sci. 1966 Dec;5(24):2279-82. PubMed PMID: 5972782.